191 related articles for article (PubMed ID: 34039392)
1. TET2 and DNMT3A mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models.
Yang SX; Hollingshead M; Rubinstein L; Nguyen D; Larenjeira ABA; Kinders RJ; Difilippantonio M; Doroshow JH
J Hematol Oncol; 2021 May; 14(1):83. PubMed ID: 34039392
[TBL] [Abstract][Full Text] [Related]
2. Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4'-thio-2'-deoxycytidine and 5-aza-4'-thio-2'-deoxycytidine.
Thottassery JV; Sambandam V; Allan PW; Maddry JA; Maxuitenko YY; Tiwari K; Hollingshead M; Parker WB
Cancer Chemother Pharmacol; 2014 Aug; 74(2):291-302. PubMed ID: 24908436
[TBL] [Abstract][Full Text] [Related]
3. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.
Scourzic L; Couronné L; Pedersen MT; Della Valle V; Diop M; Mylonas E; Calvo J; Mouly E; Lopez CK; Martin N; Fontenay M; Bender A; Guibert S; Dubreuil P; Dessen P; Droin N; Pflumio F; Weber M; Gaulard P; Helin K; Mercher T; Bernard OA
Leukemia; 2016 Jun; 30(6):1388-98. PubMed ID: 26876596
[TBL] [Abstract][Full Text] [Related]
4. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
[TBL] [Abstract][Full Text] [Related]
6. Divergent Effects of Dnmt3a and Tet2 Mutations on Hematopoietic Progenitor Cell Fitness.
Ostrander EL; Kramer AC; Mallaney C; Celik H; Koh WK; Fairchild J; Haussler E; Zhang CRC; Challen GA
Stem Cell Reports; 2020 Apr; 14(4):551-560. PubMed ID: 32220332
[TBL] [Abstract][Full Text] [Related]
7.
Maifrede S; Le BV; Nieborowska-Skorska M; Golovine K; Sullivan-Reed K; Dunuwille WMB; Nacson J; Hulse M; Keith K; Madzo J; Caruso LB; Gazze Z; Lian Z; Padella A; Chitrala KN; Bartholdy BA; Matlawska-Wasowska K; Di Marcantonio D; Simonetti G; Greiner G; Sykes SM; Valent P; Paietta EM; Tallman MS; Fernandez HF; Litzow MR; Minden MD; Huang J; Martinelli G; Vassiliou GS; Tempera I; Piwocka K; Johnson N; Challen GA; Skorski T
Cancer Res; 2021 Oct; 81(19):5089-5101. PubMed ID: 34215619
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease.
Sano S; Oshima K; Wang Y; Katanasaka Y; Sano M; Walsh K
Circ Res; 2018 Jul; 123(3):335-341. PubMed ID: 29728415
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma.
Gong F; Guo Y; Niu Y; Jin J; Zhang X; Shi X; Zhang L; Li R; Chen L; Ma RZ
Oncotarget; 2017 Jan; 8(1):315-328. PubMed ID: 27852070
[TBL] [Abstract][Full Text] [Related]
10. Lineage restriction analyses in CHIP indicate myeloid bias for
Buscarlet M; Provost S; Zada YF; Bourgoin V; Mollica L; Dubé MP; Busque L
Blood; 2018 Jul; 132(3):277-280. PubMed ID: 29764839
[TBL] [Abstract][Full Text] [Related]
11. Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.
Assmus B; Cremer S; Kirschbaum K; Culmann D; Kiefer K; Dorsheimer L; Rasper T; Abou-El-Ardat K; Herrmann E; Berkowitsch A; Hoffmann J; Seeger F; Mas-Peiro S; Rieger MA; Dimmeler S; Zeiher AM
Eur Heart J; 2021 Jan; 42(3):257-265. PubMed ID: 33241418
[TBL] [Abstract][Full Text] [Related]
12. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.
Traina F; Visconte V; Jankowska AM; Makishima H; O'Keefe CL; Elson P; Han Y; Hsieh FH; Sekeres MA; Mali RS; Kalaycio M; Lichtin AE; Advani AS; Duong HK; Copelan E; Kapur R; Olalla Saad ST; Maciejewski JP; Tiu RV
PLoS One; 2012; 7(8):e43090. PubMed ID: 22905207
[TBL] [Abstract][Full Text] [Related]
13. TET2 and DNMT3A mutations in human T-cell lymphoma.
Couronné L; Bastard C; Bernard OA
N Engl J Med; 2012 Jan; 366(1):95-6. PubMed ID: 22216861
[No Abstract] [Full Text] [Related]
14. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.
Chan SM; Majeti R
Int J Hematol; 2013 Dec; 98(6):648-57. PubMed ID: 23949914
[TBL] [Abstract][Full Text] [Related]
15. Double somatic mosaic mutations in TET2 and DNMT3A--origin of peripheral T cell lymphoma in a case.
Nguyen TB; Sakata-Yanagimoto M; Nakamoto-Matsubara R; Enami T; Ito Y; Kobayashi T; Obara N; Hasegawa Y; Chiba S
Ann Hematol; 2015 Jul; 94(7):1221-3. PubMed ID: 25687841
[No Abstract] [Full Text] [Related]
16. Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations.
Kurt H; Khoury JD; Medeiros LJ; Huh YO
Br J Haematol; 2018 May; 181(3):305. PubMed ID: 29411884
[No Abstract] [Full Text] [Related]
17. Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma.
Siraj AK; Pratheeshkumar P; Parvathareddy SK; Bu R; Masoodi T; Iqbal K; Al-Rasheed M; Al-Dayel F; Al-Sobhi SS; Alzahrani AS; Al-Dawish M; Al-Kuraya KS
Eur J Cancer; 2019 Aug; 117():133-144. PubMed ID: 31280122
[TBL] [Abstract][Full Text] [Related]
18. Clinical Implication of DNMT3A and TET2 Genes Mutations in Cytogenetically Normal Acute Myeloid Leukemia.
Aref S; Sallam N; Abd Elaziz S; Salama O; Al Ashwah S; Ayed M
Asian Pac J Cancer Prev; 2022 Dec; 23(12):4299-4305. PubMed ID: 36580013
[TBL] [Abstract][Full Text] [Related]
19. Concurrent STAT3, DNMT3A, and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential.
Raess PW; Cascio MJ; Fan G; Press R; Druker BJ; Brewer D; Spurgeon SE
Am J Hematol; 2017 Jan; 92(1):E6-E8. PubMed ID: 27761930
[No Abstract] [Full Text] [Related]
20. TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence.
Puig I; Tenbaum SP; Chicote I; Arqués O; Martínez-Quintanilla J; Cuesta-Borrás E; Ramírez L; Gonzalo P; Soto A; Aguilar S; Eguizabal C; Caratù G; Prat A; Argilés G; Landolfi S; Casanovas O; Serra V; Villanueva A; Arroyo AG; Terracciano L; Nuciforo P; Seoane J; Recio JA; Vivancos A; Dienstmann R; Tabernero J; Palmer HG
J Clin Invest; 2018 Aug; 128(9):3887-3905. PubMed ID: 29944140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
